Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
- First Posted Date
- 2013-10-14
- Last Posted Date
- 2019-12-27
- Lead Sponsor
- Celgene
- Target Recruit Count
- 107
- Registration Number
- NCT01962103
- Locations
- 🇨🇦
The Hospital for Sick Children, Toronto, Ontario, Canada
🇮🇹l'Azienda Ospedaliera Regina Margherita - Sant Anna, Torino, Italy
🇨🇭Universitäts-Kinderklinik, Zurich, Switzerland
Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)
- First Posted Date
- 2013-09-20
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 176
- Registration Number
- NCT01947309
- Locations
- 🇨🇳
Beijing Hospital, Beijing, China
🇨🇳Xiangya Hospital Central-South University, Changsha, China
🇨🇳Shanghai Changzhen Hospital, Shanghai, China
Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting
- Conditions
- Interventions
- First Posted Date
- 2013-09-19
- Last Posted Date
- 2023-05-16
- Lead Sponsor
- Celgene
- Target Recruit Count
- 186
- Registration Number
- NCT01946477
- Locations
- 🇺🇸
Local Institution - 109, Los Angeles, California, United States
🇺🇸Local Institution - 101, Hackensack, New Jersey, United States
🇺🇸CR Wood Cancer Center, Glens Falls, New York, United States
Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
- Conditions
- Interventions
- First Posted Date
- 2013-09-10
- Last Posted Date
- 2023-02-22
- Lead Sponsor
- Celgene
- Target Recruit Count
- 358
- Registration Number
- NCT01938001
- Locations
- 🇺🇸
SUNY Upstate Medical University, Syracuse, New York, United States
🇺🇸Arlington Cancer Center, Arlington, Texas, United States
🇨🇳Beijing Cancer Hospital, Beijing, PR, China
Pharmacokinetic Study of Thalidomide in Subjects With Multiple Myeloma
- First Posted Date
- 2013-09-09
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 7
- Registration Number
- NCT01937442
- Locations
- 🇫🇷
CHRU Hopital Brabois, Vandoeuvre Cedex, France
🇫🇷CHRU-Hopital Claude Huriez, Lille, France
🇫🇷Hopital Augustin Morvan, Brest Cedex, France
Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma
- First Posted Date
- 2013-08-30
- Last Posted Date
- 2014-02-04
- Lead Sponsor
- Celgene Corporation
- Registration Number
- NCT01933061
Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation
- First Posted Date
- 2013-08-05
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Celgene
- Target Recruit Count
- 345
- Registration Number
- NCT01915498
- Locations
- 🇺🇸
University of Miami Sylvester Cancer Center, Miami, Florida, United States
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms
- Conditions
- Interventions
- First Posted Date
- 2013-07-25
- Last Posted Date
- 2015-07-28
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 2
- Registration Number
- NCT01908387
- Locations
- 🇯🇵
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
🇯🇵National Cancer Center Hospital, Tokyo, Japan
🇯🇵The Cancer Institute Hospital of JFCR, Tokyo, Japan
CC-223 and Ketoconazole Drug-Drug Interaction Study
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 14
- Registration Number
- NCT01896323
Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)
- Conditions
- Interventions
- First Posted Date
- 2013-06-19
- Last Posted Date
- 2019-02-21
- Lead Sponsor
- Celgene
- Target Recruit Count
- 191
- Registration Number
- NCT01881230
- Locations
- 🇺🇸
South Carolina Oncology Associates, Columbia, South Carolina, United States
🇺🇸UT Physicians General Medicine, Houston, Texas, United States
🇧🇷Centro de Oncologia Da Bahia, Salvador, Bahia, Brazil